INSERT INTO `avella`.`drug` (`ID`, `DRUG_NAME`, `DOSAGE_ADMINISTRATION`, `DOSAGE_FORM_STRENGTH`, `CONTRAINDICTIONS`, `WARNINGS_PRECAUSTIONS`, `ADVERSE_REACTIONS`, `DRUG_INTERACTIONS`, `USE_IN_SPECIFIC_POPULATIONS`, `AVAILABLE_AT_AVELLA`, `DRUG_CATEGORY_ID`, `INDICATIONS_USAGE`, `DRUG_TYPE`, `PRESCRIBING_INFO`, `TRADE_MARK`) VALUES ('63', 'TROXYCA ER', '<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>TROXYCA ER 60 mg/7.2 mg and 80 mg/9.6 mg capsules, single doses of TROXYCA ER greater than 40 mg/4.8 mg, or a total daily dose greater than 80 mg/9.6 mg are only for use in patients in whom tolerance to an opioid of comparable potency has been established.</li>	<li>Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.</li>	<li>Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.</li><li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li><li>Instruct patients to swallow TROXYCA ER capsules intact, or to sprinkle the capsule contents on applesauce and immediately swallow without chewing.</li><li>Instruct patients not to crush, chew, or dissolve the pellets in the capsule to avoid the risk of release and absorption of a potentially fatal dose of oxycodone and to avoid release of sequestered naltrexone that could precipitate opioid withdrawal.</li>	<li>For opioid-naïve and opioid non-tolerant patients, initiate with the 10 mg/1.2 mg capsule every 12 hours.</li>	<li>Do not abruptly discontinue TROXYCA ER.</li></ul>', 'Extended-release capsules (oxycodone hydrochloride/naltrexone hydrochloride): 10 mg/1.2 mg, 20 mg/2.4 mg, 30 mg/3.6 mg, 40 mg/4.8 mg, 60 mg/7.2 mg and 80 mg/9.6 mg', '<ul><li>Significant respiratory depression</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus</li>	<li>Hypersensitivity to oxycodone or naltrexone</li></ul>', '<ul><li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.</li>	<li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li>Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of TROXYCA ER in patients with circulatory shock. (5.8)</li>	<li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of TROXYCA ER in patients with impaired consciousness or coma.</li></ul>', '<ul><li>Most common adverse reactions: nausea, constipation, vomiting, headache,and somnolence</li></ul>', '<ul><li>Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue TROXYCA ER if serotonin syndrome is suspected.</li><li>Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with TROXYCA ER because they may reduce analgesic effect of TROXYCA ER or precipitate withdrawal symptoms</li><li>Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of oxycodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.</li></ul>', '<ul><li>Pregnancy: May cause fetal harm</li><li>Lactation: Not recommended</li></ul>', '1', '1', 'TROXYCA ER is a combination opioid agonist/opioid antagonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate<br>Limitations of Use<ul><li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve TROXYCA ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li><li>TROXYCA ER is not indicated as an as-needed (prn) analgesic.</li>', '1', 'http://labeling.pfizer.com/ShowLabeling.aspx?id=4047&format=PDF', 'TROXYCA ER is a registered trademark of Pfizer Inc.');
INSERT INTO `avella`.`drug` (`ID`, `DRUG_NAME`, `DOSAGE_ADMINISTRATION`, `DOSAGE_FORM_STRENGTH`, `CONTRAINDICTIONS`, `WARNINGS_PRECAUSTIONS`, `ADVERSE_REACTIONS`, `DRUG_INTERACTIONS`, `USE_IN_SPECIFIC_POPULATIONS`, `AVAILABLE_AT_AVELLA`, `DRUG_CATEGORY_ID`, `INDICATIONS_USAGE`, `DRUG_TYPE`, `PRESCRIBING_INFO`, `TRADE_MARK`) VALUES ('64', 'VANTRELA ER', '<ul><li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li><li>VANTRELA ER 90 mg tablets, a single dose greater than 60 mg, or a total daily dose greater than 120 mg, are only for use in patients in whom tolerance to an opioid of comparable potency has been established.</li><li>Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.</li><li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.</li><li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li><li>Tablets must be swallowed intact and are not to be crushed, dissolved, or chewed due to the risk of overdose or death.</li>	<li>For opioid-naïve and opioid non-tolerant patients, initiate with 15 mg tablets orally every 12 hours.</li>	<li>To convert to VANTRELA ER from another opioid, always consider starting at the lowest dose or follow the conversion instructions to obtain an estimated dose.</li><li>Increase dose every 3 to 7 days as needed.</li>	<li>Do not abruptly discontinue VANTRELA ER in a physically-dependent patient.</li>	<li>Mild to Moderate Hepatic Impairment: Initiate therapy with one half of the recommended initial dose and titrate carefully. Use alternative analgesia for patients requiring less than 15 mg. Monitor closely.</li>	<li>Moderate to Severe Renal Impairment and End Stage Renal Disease: Initiate therapy with one half of the recommended initial dose and titrate carefully. Use alternative analgesia for patients requiring less than 15 mg. Monitor closely.</li></ul>', '<ul><li>Extended-release tablets: 15 mg, 30 mg, 45 mg, 60 mg and 90 mg</li></ul>', '<ul><li>Significant respiratory depression</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus</li>	<li>Hypersensitivity to hydrocodone bitartrate</li></ul>', '<ul><li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease and in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.</li>	<li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li><li>Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of VANTRELA ER in patients with circulatory shock.</li>	<li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use in patients with impaired consciousness or coma.</li>	<li>QTc Prolongation: Consider this observation when making clinical decisions regarding monitoring of patients with congestive heart failure, bradyarrhythmia, or electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. Avoid use in patients with congenital long QTc syndrome. In patients who develop QTc prolongation, consider reducing the dose. Do not exceed a dose of 90 mg every 12 hours (180 mg per day). Higher doses have not been studied.</li></ul>', '<ul><li>Adverse reactions in =2% of patients in placebo-controlled trials include nausea, constipation, headache, somnolence, vomiting, dizziness, pruritus, fatigue, dry mouth, diarrhea, insomnia, anxiety.</li></ul>', '<ul><li>Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue VANTRELA ER if serotonin syndrome is suspected.</li><li>Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of hydrocodone. Avoid VANTRELA ER in patients receiving MAOIs or within 14 days of stopping an MAOI.</li><li>Mixed Agonists/Antagonists and Partial Agonist Analgesics: Avoid use with VANTRELA ER because they may reduce analgesic effect of VANTRELA ER or precipitate withdrawal symptoms.</li></ul>', '<ul><li>Pregnancy: Based on animal data, may cause fetal harm.</li><li>Nursing mothers: Nursing is not recommended.</li>	<li>Severe Hepatic Impairment: Use not recommended.</li></ul>', '1', '1', 'VANTRELA ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.<br>Limitations of Use', '1', 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207975s000lbl.pdf', 'VANTRELA ER is a registered trademark of Teva Pharmaceuticals USA Inc.,');


INSERT INTO `avella`.`drug` (`ID`, `DRUG_NAME`, `DOSAGE_ADMINISTRATION`, `DOSAGE_FORM_STRENGTH`, `CONTRAINDICTIONS`, `WARNINGS_PRECAUSTIONS`, `ADVERSE_REACTIONS`, `DRUG_INTERACTIONS`, `USE_IN_SPECIFIC_POPULATIONS`, `AVAILABLE_AT_AVELLA`, `DRUG_CATEGORY_ID`, `INDICATIONS_USAGE`, `DRUG_TYPE`, `PRESCRIBING_INFO`, `TRADE_MARK`) VALUES ('65', 'BELBUCA', '<ul><li>To be prescribed only by health care providers knowledgeable in use of potent opioids for management of chronic pain.</li><li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.</li><li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li><li>For opioid-naïve patients: Initiate therapy with 75 mcg BELBUCA once daily or every 12 hours, as tolerated, for at least 4 days before increasing dose to 150 mcg every 12 hours.</li><li>Conversion from other opioids to BELBUCA: Taper current daily opioid dose to 30 mg oral morphine sulfate equivalents (MSE) or less prior to initiating therapy with BELBUCA.</li><li>For patients taking less than 30 mg oral MSE, initiate therapy with 75 mcg once daily or every 12 hours.</li><li>For patients taking between 30 mg and 89 mg oral MSE, initiate therapy with 150 mcg BELBUCA every 12 hours following analgesic taper.</li>	<li>For patients taking between 90 mg and 160 mg oral MSE, initiate therapy with 300 mcg BELBUCA every 12 hours following analgesic taper.</li>	<li>For patients taking greater than 160 mg oral MSE, consider alternate analgesic.</li>	<li>BELBUCA doses of 600 mcg, 750 mcg, and 900 mcg are only for use following titration from lower doses of BELBUCA.</li>	<li>Do not abruptly discontinue BELBUCA in a physically-dependent patient.</li><li>Patients with Severe Hepatic Impairment: Reduce the starting and incremental dose by half that of patients with normal liver function.</li>	<li>Patients with Oral Mucositis: Reduce the starting and incremental dose by half that of patients without mucositis.</li></ul>', '<ul><li>Buccal film available in 75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg, and 900 mcg dosage strengths</li></ul>', '<ul><li>Significant respiratory depression.</li><li>Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment.</li><li>Known or suspected gastrointestinal obstruction, including paralytic ileus.</li>	<li>Hypersensitivity to buprenorphine.</li></ul>', '<ul><li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.</li>	<li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li>Risk of Prolonged QTc Interval: Avoid in patients with Long QT Syndrome, family history of Long QT Syndrome, or those taking Class IA or Class III antiarrhythmic medications.</li>	<li>Severe Hypotension: Monitor during dose initiation and titration. Avoid use of BELBUCA in patients with circulatory shock.</li>	<li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of BELBUCA in patients with impaired consciousness or coma.</li></ul>', '<ul><li>Most common adverse reactions (&gt;5%) include nausea, constipation, headache, vomiting, dizziness, and somnolence.</li></ul>', '<ul><li>Benzodiazepines: May increase buprenorphine-induced respiratory depression. Monitor patients on concurrent therapy closely.</li>	<li>CYP3A4 Inhibitors/Inducers: Initiating CYP3A4 inhibitors or discontinuing CYP3A4 inducers may result in an increase in buprenorphine plasma concentrations. Closely monitor patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers for respiratory depression.</li>	<li>Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue BELBUCA if serotonin syndrome is suspected.</li>	<li>Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with BELBUCA because they may reduce analgesic effect of BELBUCA or precipitate withdrawal symptoms.</li>	<li>Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of buprenorphine. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.</li></ul>', '<ul><li>Pregnancy: Based on animal data, may cause fetal harm.</li><li>Nursing mothers: Nursing is not recommended.</li><li>Moderate or Severe Hepatic Impairment: Monitor for signs and symptoms of toxicity or overdose.</li></ul>', '1', '1', 'BELBUCA buccal film contains buprenorphine, a partial opioid agonist. BELBUCA is indicated for the management of pain severe enough to require daily, around-the clock, long-term opioid treatment and for which alternative treatment options are inadequate.<br>Limitations of Use<ul>	<li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with long-acting opioid formulations, reserve BELBUCA for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li><li>BELBUCA is not indicated as an as-needed (prn) analgesic.</li></ul>', '1', 'https://s3.amazonaws.com/belbuca/website/pdfs/belbuca-prescribing-info.pdf', 'BELBUCA is a registered trademark of BioDelivery Sciences International Inc.');
